{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:57:59Z","timestamp":1784059079715,"version":"3.55.0"},"reference-count":137,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Intramural Research Program, National Institute on Aging, National Institutes of Health, USA","award":["AG000994"],"award-info":[{"award-number":["AG000994"]}]},{"name":"The Intramural Research Program, National Institute on Aging, National Institutes of Health, USA","award":["R56 AG057028"],"award-info":[{"award-number":["R56 AG057028"]}]},{"name":"The Intramural Research Program, National Institute on Aging, National Institutes of Health, USA","award":["S2782046"],"award-info":[{"award-number":["S2782046"]}]},{"name":"The Intramural Research Program, National Institute on Aging, National Institutes of Health, USA","award":["2021M3A9G2015889"],"award-info":[{"award-number":["2021M3A9G2015889"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG000994"],"award-info":[{"award-number":["AG000994"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R56 AG057028"],"award-info":[{"award-number":["R56 AG057028"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S2782046"],"award-info":[{"award-number":["S2782046"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2021M3A9G2015889"],"award-info":[{"award-number":["2021M3A9G2015889"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Duane and Joyce Collins Neurosurgery Fund, Department of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA","award":["AG000994"],"award-info":[{"award-number":["AG000994"]}]},{"name":"The Duane and Joyce Collins Neurosurgery Fund, Department of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA","award":["R56 AG057028"],"award-info":[{"award-number":["R56 AG057028"]}]},{"name":"The Duane and Joyce Collins Neurosurgery Fund, Department of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA","award":["S2782046"],"award-info":[{"award-number":["S2782046"]}]},{"name":"The Duane and Joyce Collins Neurosurgery Fund, Department of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA","award":["2021M3A9G2015889"],"award-info":[{"award-number":["2021M3A9G2015889"]}]},{"name":"Technology Development Program of MSS","award":["AG000994"],"award-info":[{"award-number":["AG000994"]}]},{"name":"Technology Development Program of MSS","award":["R56 AG057028"],"award-info":[{"award-number":["R56 AG057028"]}]},{"name":"Technology Development Program of MSS","award":["S2782046"],"award-info":[{"award-number":["S2782046"]}]},{"name":"Technology Development Program of MSS","award":["2021M3A9G2015889"],"award-info":[{"award-number":["2021M3A9G2015889"]}]},{"name":"National Research Foundation (NRF) grant funded by the Korean government","award":["AG000994"],"award-info":[{"award-number":["AG000994"]}]},{"name":"National Research Foundation (NRF) grant funded by the Korean government","award":["R56 AG057028"],"award-info":[{"award-number":["R56 AG057028"]}]},{"name":"National Research Foundation (NRF) grant funded by the Korean government","award":["S2782046"],"award-info":[{"award-number":["S2782046"]}]},{"name":"National Research Foundation (NRF) grant funded by the Korean government","award":["2021M3A9G2015889"],"award-info":[{"award-number":["2021M3A9G2015889"]}]},{"name":"Korea Research Institute of Bioscience and Biotechnology Research Initiative Program Grants","award":["AG000994"],"award-info":[{"award-number":["AG000994"]}]},{"name":"Korea Research Institute of Bioscience and Biotechnology Research Initiative Program Grants","award":["R56 AG057028"],"award-info":[{"award-number":["R56 AG057028"]}]},{"name":"Korea Research Institute of Bioscience and Biotechnology Research Initiative Program Grants","award":["S2782046"],"award-info":[{"award-number":["S2782046"]}]},{"name":"Korea Research Institute of Bioscience and Biotechnology Research Initiative Program Grants","award":["2021M3A9G2015889"],"award-info":[{"award-number":["2021M3A9G2015889"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Traumatic brain injury (TBI) is a major risk factor for several neurodegenerative disorders, including Parkinson\u2019s disease (PD) and Alzheimer\u2019s disease (AD). Neuroinflammation is a cause of later secondary cell death following TBI, has the potential to aggravate the initial impact, and provides a therapeutic target, albeit that has failed to translate into clinical trial success. Thalidomide-like compounds have neuroinflammation reduction properties across cellular and animal models of TBI and neurodegenerative disorders. They lower the generation of proinflammatory cytokines, particularly TNF-\u03b1 which is pivotal in microglial cell activation. Unfortunately, thalidomide-like drugs possess adverse effects in humans before achieving anti-inflammatory drug levels. We developed F-3,6\u2032-dithiopomalidomide (F-3,6\u2032-DP) as a novel thalidomide-like compound to ameliorate inflammation. F-3,6\u2032-DP binds to cereblon but does not efficiently trigger the degradation of the transcription factors (SALL4, Ikaros, and Aiolos) associated with the teratogenic and anti-proliferative responses of thalidomide-like drugs. We utilized a phenotypic drug discovery approach that employed cellular and animal models in the selection and development of F-3,6\u2019-DP. F-3,6\u2032-DP significantly mitigated LPS-induced inflammatory markers in RAW 264.7 cells, and lowered proinflammatory cytokine\/chemokine levels in the plasma and brain of rats challenged with systemic LPS. We subsequently examined immunohistochemical, biochemical, and behavioral measures following controlled cortical impact (CCI) in mice, a model of moderate TBI known to induce inflammation. F-3,6\u2032-DP decreased CCI-induced neuroinflammation, neuronal loss, and behavioral deficits when administered after TBI. F-3,6\u2032-DP represents a novel class of thalidomide-like drugs that do not lower classical cereblon-associated transcription factors but retain anti-inflammatory actions and possess efficacy in the treatment of TBI and potentially longer-term neurodegenerative disorders.<\/jats:p>","DOI":"10.3390\/biomedicines10102449","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:07:43Z","timestamp":1665187663000},"page":"2449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Activity of a Novel Anti-Inflammatory Agent F-3,6\u2032-dithiopomalidomide as a Treatment for Traumatic Brain Injury"],"prefix":"10.3390","volume":"10","author":[{"given":"Shih Chang","family":"Hsueh","sequence":"first","affiliation":[{"name":"Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program National Institute on Aging, NIH, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Scerba","sequence":"additional","affiliation":[{"name":"Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program National Institute on Aging, NIH, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tweedie","sequence":"additional","affiliation":[{"name":"Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program National Institute on Aging, NIH, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Lecca","sequence":"additional","affiliation":[{"name":"Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program National Institute on Aging, NIH, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"AevisBio, Inc., Gaithersburg, MD 20878, USA"},{"name":"Aevis Bio, Inc., Daejeon 34141, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Mannan","family":"Baig","sequence":"additional","affiliation":[{"name":"Department of Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Kyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Aevis Bio, Inc., Daejeon 34141, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inho","family":"Hwang","sequence":"additional","affiliation":[{"name":"Aevis Bio, Inc., Daejeon 34141, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Kim","sequence":"additional","affiliation":[{"name":"Aevis Bio, Inc., Daejeon 34141, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren R.","family":"Selman","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Case Western Reserve University and University Hospitals, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Hoffer","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Case Western Reserve University and University Hospitals, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3032-1468","authenticated-orcid":false,"given":"Nigel H.","family":"Greig","sequence":"additional","affiliation":[{"name":"Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program National Institute on Aging, NIH, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3171\/2017.10.JNS17352","article-title":"Estimating the global incidence of traumatic brain injury","volume":"130","author":"Dewan","year":"2018","journal-title":"J. Neurosurg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12640-011-9297-0","article-title":"Influence of physical exercise on traumatic brain injury deficits: Scaffolding effect","volume":"21","author":"Archer","year":"2012","journal-title":"Neurotox. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3233\/NRE-141074","article-title":"Traumatic brain injury and neuro-endocrine disruption: Medical and psychosocial rehabilitation","volume":"34","author":"Webb","year":"2014","journal-title":"NeuroRehabilitation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.apmr.2008.10.013","article-title":"Incidence of gait abnormalities after traumatic brain injury","volume":"90","author":"Williams","year":"2009","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2016.1948","article-title":"Association of Traumatic Brain Injury with Late-Life Neurodegenerative Conditions and Neuropathologic Findings","volume":"73","author":"Crane","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.mehy.2013.07.025","article-title":"alpha-Synuclein is a pathological link and therapeutic target for Parkinson\u2019s disease and traumatic brain injury","volume":"81","author":"Shahaduzzaman","year":"2013","journal-title":"Med. Hypotheses"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/10408363.2013.844678","article-title":"Parkinson\u2019s disease, parkinsonism, and traumatic brain injury","volume":"50","author":"Wong","year":"2013","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S2215-0366(18)30065-8","article-title":"Long-term risk of dementia among people with traumatic brain injury in Denmark: A population-based observational cohort study","volume":"5","author":"Fann","year":"2018","journal-title":"Lancet Psychiatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1771","DOI":"10.1212\/WNL.0000000000005522","article-title":"Mild TBI and risk of Parkinson disease: A Chronic Effects of Neurotrauma Consortium Study","volume":"90","author":"Gardner","year":"2018","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1146\/annurev.immunol.021908.132557","article-title":"Blood monocytes: Development, heterogeneity, and relationship with dendritic cells","volume":"27","author":"Auffray","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00381-009-1029-x","article-title":"What has inflammation to do with traumatic brain injury?","volume":"26","author":"Cederberg","year":"2010","journal-title":"Childs Nerv. Syst."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.expneurol.2008.02.001","article-title":"Systemic inflammation exacerbates behavioral and histopathological consequences of isolated traumatic brain injury in rats","volume":"211","author":"Utagawa","year":"2008","journal-title":"Exp. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrneurol.2013.36","article-title":"Acute and chronic traumatic encephalopathies: Pathogenesis and biomarkers","volume":"9","author":"DeKosky","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/j.1528-1167.2005.00298.x","article-title":"Brain inflammation in epilepsy: Experimental and clinical evidence","volume":"46","author":"Vezzani","year":"2005","journal-title":"Epilepsia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00075198-200204000-00002","article-title":"Inflammatory response in acute traumatic brain injury: A double-edged sword","volume":"8","author":"Rancan","year":"2002","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12974-016-0786-1","article-title":"Inflammation in epileptogenesis after traumatic brain injury","volume":"14","author":"Webster","year":"2017","journal-title":"J. Neuroinflamm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jneumeth.2016.06.018","article-title":"Neuroinflammation in animal models of traumatic brain injury","volume":"272","author":"Chiu","year":"2016","journal-title":"J. Neurosci. Methods"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.tips.2010.09.005","article-title":"Neuroprotection for traumatic brain injury: Translational challenges and emerging therapeutic strategies","volume":"31","author":"Loane","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8385961","DOI":"10.1155\/2017\/8385961","article-title":"Sterile Neuroinflammation and Strategies for Therapeutic Intervention","volume":"2017","author":"Banjara","year":"2017","journal-title":"Int. J. Inflamm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1089\/neu.1999.16.1023","article-title":"Prolonged activation of NF-kappaB following traumatic brain injury in rats","volume":"16","author":"Nonaka","year":"1999","journal-title":"J. Neurotrauma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8721","DOI":"10.1073\/pnas.96.15.8721","article-title":"Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury","volume":"96","author":"Scherbel","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/00003246-200004000-00054","article-title":"Interleukin-8, neuroinflammation, and secondary brain injury","volume":"28","author":"Sherwood","year":"2000","journal-title":"Crit. Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.pharmthera.2010.08.007","article-title":"The roles of TNF in brain dysfunction and disease","volume":"128","author":"Clark","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fneur.2013.00018","article-title":"The role of markers of inflammation in traumatic brain injury","volume":"4","author":"Woodcock","year":"2013","journal-title":"Front. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fnmol.2012.00006","article-title":"The cytokine temporal profile in rat cortex after controlled cortical impact","volume":"5","author":"Dalgard","year":"2012","journal-title":"Front. Mol. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","article-title":"Tumor necrosis factor-alpha signaling in macrophages","volume":"20","author":"Parameswaran","year":"2010","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6101(99)00008-8","article-title":"Dual role of tumor necrosis factor alpha in brain injury","volume":"10","author":"Shohami","year":"1999","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/jcbfm.2013.65","article-title":"Tumor necrosis factor in traumatic brain injury: Effects of genetic deletion of p55 or p75 receptor","volume":"33","author":"Longhi","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1179573517709278","DOI":"10.1177\/1179573517709278","article-title":"Tumor necrosis factor alpha Inhibition for Alzheimer\u2019s Disease","volume":"9","author":"Chang","year":"2017","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1523\/JNEUROSCI.2484-16.2017","article-title":"Peripheral Tumor Necrosis Factor-Alpha (TNF-alpha) Modulates Amyloid Pathology by Regulating Blood-Derived Immune Cells and Glial Response in the Brain of AD\/TNF Transgenic Mice","volume":"37","author":"Paouri","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0304-3940(94)90746-3","article-title":"Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients","volume":"165","author":"Mogi","year":"1994","journal-title":"Neurosci. Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neulet.2017.08.049","article-title":"Tumor necrosis factor alpha polymorphisms are associated with Parkinson\u2019s disease age at onset","volume":"658","author":"Lindenau","year":"2017","journal-title":"Neurosci. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Fresegna, D., Bullitta, S., Musella, A., Rizzo, F.R., De Vito, F., Guadalupi, L., Caioli, S., Balletta, S., Sanna, K., and Dolcetti, E. (2020). Re-Examining the Role of TNF in MS Pathogenesis and Therapy. Cells, 9.","DOI":"10.3390\/cells9102290"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/1352458513498128","article-title":"Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration","volume":"20","author":"Rossi","year":"2014","journal-title":"Mult. Scler."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Guidotti, G., Scarlata, C., Brambilla, L., and Rossi, D. (2021). Tumor Necrosis Factor Alpha in Amyotrophic Lateral Sclerosis: Friend or Foe?. Cells, 9.","DOI":"10.3390\/cells10030518"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2985051","DOI":"10.1155\/2017\/2985051","article-title":"Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNFalpha","volume":"2017","author":"Tortarolo","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/neu.2009.1120","article-title":"In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury","volume":"27","author":"Frugier","year":"2010","journal-title":"J. Neurotrauma"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0165-5728(99)00148-4","article-title":"IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: Relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function","volume":"101","author":"Csuka","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/exnr.1994.1114","article-title":"Contribution of peripheral macrophages and microglia to the cellular reaction after mechanical or neurotoxin-induced lesions of the rat brain","volume":"128","author":"Fardeau","year":"1994","journal-title":"Exp. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0165-5728(96)00181-6","article-title":"Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant","volume":"72","author":"Shohami","year":"1997","journal-title":"J. Neuroimmunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12974-020-02005-x","article-title":"Cellular infiltration in traumatic brain injury","volume":"17","author":"Alam","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/978-3-211-85578-2_80","article-title":"Effect of traumatic brain injury on cognitive function in mice lacking p55 and p75 tumor necrosis factor receptors","volume":"102","author":"Longhi","year":"2008","journal-title":"Acta Neurochir. Suppl."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/sj.jcbfm.9600487","article-title":"TNF alpha and Fas mediate tissue damage and functional outcome after traumatic brain injury in mice","volume":"27","author":"Berrrrpohl","year":"2007","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1476-5381.1960.tb01217.x","article-title":"Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug","volume":"15","author":"Somers","year":"1960","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J. Exp. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0165-2478(99)00055-3","article-title":"Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: Comparisons with dexamethasone","volume":"68","author":"Rowland","year":"1999","journal-title":"Immunol. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1021\/jm030152f","article-title":"Thiothalidomides: Novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity","volume":"46","author":"Zhu","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/S0140-6736(78)92436-4","article-title":"Teratogenic action of thalidomide","volume":"311","author":"McBride","year":"1978","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/bdrc.21096","article-title":"Thalidomide-induced teratogenesis: History and mechanisms","volume":"105","author":"Vargesson","year":"2015","journal-title":"Birth Defects Res. Part C Embryo Today Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(63)91347-3","article-title":"Thalidomide and congenital abnormalities","volume":"281","author":"Yang","year":"1963","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"Loughnan","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1749-6632.2011.05974.x","article-title":"A review of the history, properties, and use of the immunomodulatory compound lenalidomide","volume":"1222","author":"Zeldis","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2613.2002.00219.x","article-title":"Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma","volume":"83","author":"Arrieta","year":"2002","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Mendy","year":"2012","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1345\/aph.1H038","article-title":"Novel therapies for Crohn\u2019s disease: Focus on immunomodulators and antibiotics","volume":"40","author":"Wilhelm","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3816\/CLM.2009.n.053","article-title":"Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide","volume":"9","author":"Kurtin","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1038\/onc.2012.599","article-title":"Thalidomide-analogue biology: Immunological, molecular and epigenetic targets in cancer therapy","volume":"32","author":"Shortt","year":"2013","journal-title":"Oncogene"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"11163","DOI":"10.1021\/acsomega.8b00959","article-title":"Chemical Ligand Space of Cereblon","volume":"3","author":"Boichenko","year":"2018","journal-title":"ACS Omega"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ddtec.2019.02.004","article-title":"Cereblon modulators: Low molecular weight inducers of protein degradation","volume":"31","author":"Chamberlain","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/clpt.2012.236","article-title":"Phenotypic vs. target-based drug discovery for first-in-class medicines","volume":"93","author":"Swinney","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.bmc.2018.01.032","article-title":"Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF-alpha and angiogenesis inhibitory activities","volume":"26","author":"Luo","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"656921","DOI":"10.3389\/fnins.2021.656921","article-title":"Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders","volume":"15","author":"Jung","year":"2021","journal-title":"Front. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"12703","DOI":"10.1073\/pnas.1307684110","article-title":"Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro","volume":"110","author":"Mahony","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1634\/theoncologist.2014-0073","article-title":"The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: Summary of the scientific assessment of the committee for medicinal products for human use","volume":"20","author":"Hanaizi","year":"2015","journal-title":"Oncologist"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12974-016-0631-6","article-title":"Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat","volume":"13","author":"Wang","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0963689719850078","article-title":"Pomalidomide Reduces Ischemic Brain Injury in Rodents","volume":"28","author":"Tsai","year":"2019","journal-title":"Cell Transpl."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1055\/s-0040-1720460","article-title":"Thionation of Aminophthalimide Hindered Carbonyl Groups and Application to the Synthesis of 3,6\u2032-Dithionated Pomalidomides","volume":"32","author":"Scerba","year":"2021","journal-title":"Synlett"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1021\/acs.chemrestox.0c00439","article-title":"Metabolism and Toxicity of Fluorine Compounds","volume":"34","author":"Kyzer","year":"2021","journal-title":"Chem. Res. Toxicol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Lecca, D., Jung, Y.J., Scerba, M.T., Hwang, I., Kim, Y.K., Kim, S., Modrow, S., Tweedie, D., Hsueh, S.C., and Liu, D. (Alzheimers Dement., 2022). Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis, Alzheimers Dement., ahead of print.","DOI":"10.1002\/alz.12610"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Tsai, Y.R., Kim, D.S., Hsueh, S.C., Chen, K.Y., Wu, J.C., Wang, J.Y., Tsou, Y.S., Hwang, I., Kim, Y.K., and Gil, D. (2022). 3,6\u2032-and 1,6\u2032-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14050950"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2019.06.004","article-title":"Molecular mechanisms of cereblon-based drugs","volume":"202","author":"Ito","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","article-title":"SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate","volume":"14","author":"Matyskiela","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e54726","DOI":"10.7554\/eLife.54726","article-title":"3,6\u2019-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation","volume":"9","author":"Lin","year":"2020","journal-title":"eLife"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/acs.jcim.7b00190","article-title":"PlayMolecule ProteinPrepare: A Web Application for Protein Preparation for Molecular Dynamics Simulations","volume":"57","author":"Giorgino","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1093\/bioinformatics\/btx350","article-title":"DeepSite: Protein-binding site predictor using 3D-convolutional neural networks","volume":"33","author":"Jimenez","year":"2017","journal-title":"Bioinformatics"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41401-019-0228-6","article-title":"CB-Dock: A web server for cavity detection-guided protein-ligand blind docking","volume":"41","author":"Liu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/B978-0-444-52892-6.00004-0","article-title":"The neuropathology of traumatic brain injury","volume":"127","author":"McKee","year":"2015","journal-title":"Handb. Clin. Neurol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41598-017-01747-8","article-title":"Characterizing microglia activation: A spatial statistics approach to maximize information extraction","volume":"7","author":"Davis","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2174\/187152711794653751","article-title":"Targeting TNF-alpha to elucidate and ameliorate neuroinflammation in neurodegenerative diseases","volume":"10","author":"Frankola","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1742-2094-10-84","article-title":"Down\u2019s syndrome, neuroinflammation, and Alzheimer neuropathogenesis","volume":"10","author":"Wilcock","year":"2013","journal-title":"J. Neuroinflamm."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12974-016-0708-2","article-title":"Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents","volume":"13","author":"Clark","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2174\/1381612824666180327170632","article-title":"The Role of Inflammation in Neurological Disorders","volume":"24","author":"Degan","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.aag2590","article-title":"How neuroinflammation contributes to neurodegeneration","volume":"353","author":"Ransohoff","year":"2016","journal-title":"Science"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/1567205054367883","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease","volume":"2","author":"Klegeris","year":"2005","journal-title":"Curr. Alzheimer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1212\/01.wnl.0000311269.57716.63","article-title":"Protective effects of NSAIDs on the development of Alzheimer disease","volume":"70","author":"Vlad","year":"2008","journal-title":"Neurology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fnagi.2018.00083","article-title":"NSAID Exposure and Risk of Alzheimer\u2019s Disease: An Updated Meta-Analysis from Cohort Studies","volume":"10","author":"Zhang","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41582-019-0307-9","article-title":"In search of an anti-inflammatory drug for Alzheimer disease","volume":"16","author":"Gyengesi","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuropharm.2018.04.006","article-title":"Repurposing and repositioning neurosteroids in the treatment of traumatic brain injury: A report from the trenches","volume":"147","author":"Stein","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fneur.2020.00348","article-title":"Inflammatory Cytokines Associate with Neuroimaging After Acute Mild Traumatic Brain Injury","volume":"11","author":"Edwards","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3389\/fneur.2019.01120","article-title":"Elevated Serum Levels of Inflammation-Related Cytokines in Mild Traumatic Brain Injury Are Associated with Cognitive Performance","volume":"10","author":"Sun","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fnagi.2017.00194","article-title":"Aging Microglia-Phenotypes, Functions and Implications for Age-Related Neurodegenerative Diseases","volume":"9","author":"Spittau","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/jnc.14860","article-title":"Microglia and the aging brain: Are senescent microglia the key to neurodegeneration?","volume":"151","author":"Angelova","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"861231","DOI":"10.1155\/2014\/861231","article-title":"Tumor necrosis factor alpha: A link between neuroinflammation and excitotoxicity","volume":"2014","author":"Olmos","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00281-017-0628-y","article-title":"The meteorology of cytokine storms, and the clinical usefulness of this knowledge","volume":"39","author":"Clark","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0165-5728(98)00273-2","article-title":"Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment","volume":"95","author":"Knoblach","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/brain\/awx339","article-title":"Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration","volume":"141","author":"Scott","year":"2018","journal-title":"Brain"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"13211","DOI":"10.1038\/s41598-017-13581-z","article-title":"Quantitative microglia analyses reveal diverse morphologic responses in the rat cortex after diffuse brain injury","volume":"7","author":"Morrison","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fnagi.2017.00208","article-title":"Microglial Activation in Traumatic Brain Injury","volume":"9","author":"Donat","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/s41598-022-05815-6","article-title":"Automated characterisation of microglia in ageing mice using image processing and supervised machine learning algorithms","volume":"12","author":"Choi","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/0271678X17699223","article-title":"(11)C-DPA-713 has much greater specific binding to translocator protein 18 kDa (TSPO) in human brain than (11)C-(R)-PK11195","volume":"38","author":"Kobayashi","year":"2018","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/ana.22455","article-title":"Inflammation after trauma: Microglial activation and traumatic brain injury","volume":"70","author":"Ramlackhansingh","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/1742-2094-9-232","article-title":"Evaluation of age-related changes in translocator protein (TSPO) in human brain using (11)C-[R]-PK11195 PET","volume":"9","author":"Kumar","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"ref_107","unstructured":"George, K., and Das, J.M. (2022). Neuroanatomy, Thalamocortical Radiations, StatPearls."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Dever, A., Powell, D., Graham, L., Mason, R., Das, J., Marshall, S.J., Vitorio, R., Godfrey, A., and Stuart, S. (2022). Gait Impairment in Traumatic Brain Injury: A Systematic Review. Sensors, 22.","DOI":"10.3390\/s22041480"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1097\/HTR.0000000000000038","article-title":"Classification of gait disorders following traumatic brain injury","volume":"30","author":"Williams","year":"2015","journal-title":"J. Head Trauma Rehabil."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Kobeissy, F.H. (2015). Controlled Cortical Impact Model. Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects, CRC Press\/Taylor & Francis.","DOI":"10.1201\/b18126"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.brainres.2009.06.067","article-title":"Severity of controlled cortical impact traumatic brain injury in rats and mice dictates degree of behavioral deficits","volume":"1287","author":"Yu","year":"2009","journal-title":"Brain Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"113210","DOI":"10.1016\/j.bbr.2021.113210","article-title":"Gait analysis in a rat model of traumatic brain injury","volume":"405","author":"Reed","year":"2021","journal-title":"Behav. Brain Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bbr.2015.02.038","article-title":"Evaluation of gait impairment in mice subjected to craniotomy and traumatic brain injury","volume":"286","author":"Sashindranath","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/neu.2010.1427","article-title":"Craniotomy: True sham for traumatic brain injury, or a sham of a sham?","volume":"28","author":"Cole","year":"2011","journal-title":"J. Neurotrauma"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fneur.2012.00155","article-title":"Controlled cortical impact and craniotomy induce strikingly similar profiles of inflammatory gene expression, but with distinct kinetics","volume":"3","author":"Lagraoui","year":"2012","journal-title":"Front. Neurol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1152\/jn.00978.2016","article-title":"The neural control of interlimb coordination during mammalian locomotion","volume":"117","author":"Frigon","year":"2017","journal-title":"J. Neurophysiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.brainres.2012.05.008","article-title":"Microglia activation along the corticospinal tract following traumatic brain injury in the rat: A neuroanatomical study","volume":"1465","author":"Jacobowitz","year":"2012","journal-title":"Brain Res."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Batsaikhan, B., Wang, J.Y., Scerba, M.T., Tweedie, D., Greig, N.H., Miller, J.P., Hoffer, B.J., Lin, C.T., and Wang, J.Y. (2019). Post-Injury Neuroprotective Effects of the Thalidomide Analog 3,6\u2019-Dithiothalidomide on Traumatic Brain Injury. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030502"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12974-015-0237-4","article-title":"Transiently lowering tumor necrosis factor-alpha synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice","volume":"12","author":"Baratz","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"629326","DOI":"10.3389\/fcell.2021.629326","article-title":"Cereblon-based small-molecule compounds to control neural stem cell proliferation in regenerative medicine","volume":"9","author":"Sato","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"29573","DOI":"10.1074\/jbc.M113.472092","article-title":"A mental retardation-linked nonsense mutation in cereblon is rescued by proteasome inhibition","volume":"288","author":"Xu","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12185-016-2073-4","article-title":"Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs","volume":"104","author":"Ito","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"9130608","DOI":"10.1155\/2017\/9130608","article-title":"Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation","volume":"2017","author":"Shi","year":"2017","journal-title":"J. Immunol. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1249543","article-title":"How thalidomide works against cancer","volume":"343","author":"Stewart","year":"2014","journal-title":"Science"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41594-020-0405-9","article-title":"Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex","volume":"27","author":"Matyskiela","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1073\/pnas.1814446115","article-title":"Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs","volume":"115","author":"Gemechu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.1074\/jbc.RA118.002246","article-title":"Cereblon suppresses the lipopolysaccharide-induced inflammatory response by promoting the ubiquitination and degradation of c-Jun","volume":"293","author":"Yang","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","article-title":"Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice","volume":"132","author":"Fink","year":"2018","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e2313","DOI":"10.1038\/cddis.2016.226","article-title":"Cereblon negatively regulates TLR4 signaling through the attenuation of ubiquitination of TRAF6","volume":"7","author":"Min","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1021\/acsptsci.1c00042","article-title":"N-Adamantyl phthalimidine: A new thalidomide-like drug that lacks cereblon binding and mitigates neuronal and synaptic loss, neuroinflammation, and behavioral deficits in traumatic brain injury and LPS challenge","volume":"4","author":"Hsueh","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/1753193418805249","article-title":"The teratogenic effects of thalidomide on limbs","volume":"44","author":"Vargesson","year":"2019","journal-title":"J. Hand Surg."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1089\/neu.2018.6171","article-title":"Sex differences in traumatic brain injury: What we know and what we should know","volume":"36","author":"Gupte","year":"2019","journal-title":"J. Neurotrauma"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3389\/fnagi.2017.00430","article-title":"Role of estrogen and other sex hormones in brain aging. neuroprotection and DNA repair","volume":"9","author":"Stevnsner","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol. Sex Differ."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:52Z","timestamp":1760143492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":137,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["biomedicines10102449"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10102449","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}